• CP-673451: A PDGFR Assay Design Guide

  2026-09-10

  CP-673451 is a selective PDGFRα/β inhibitor whose value extends beyond nanomolar potency. This guide shows how to connect biochemical selectivity, PDGFR-β phosphorylation, angiogenesis inhibition assay design, ATRX biology, and xenograft interpretation without confusing target engagement with antitumor efficacy.

• Diuron-Induced Acute Kidney Injury: Study Insights

  2026-09-10

  This 2025 study integrates network toxicology, molecular docking, transcriptomic validation, and HK-2 cell experiments to investigate how Diuron may cause acute kidney injury. Its results prioritize JAK2/STAT1 signaling as a mechanistic pathway while defining the limits of computational and in vitro evidence for environmental toxicology.

• BMS-777607: A Practical c-Met Inhibitor Guide

  2026-09-09

  BMS-777607 is a selective c-Met inhibitor for dissecting MET-family signaling in cancer metastasis models and exploratory stem-cell differentiation assays. This guide separates validated oncology use cases from emerging hiPSC platelet applications, with practical dosing, controls, and troubleshooting strategies.

• CP-673451 and the Next Logic of PDGFR Translation

  2026-09-09

  CP-673451 offers a focused way to connect PDGFR biology with translational decision-making. This thought-leadership article examines how its ATP-competitive selectivity can clarify receptor phosphorylation, angiogenesis, and tumor response while incorporating ATRX status into glioma research. It also provides an assay-centered framework, practical protocol parameters, competitive context, and guardrails for interpreting xenograft findings without overstating preclinical evidence.

• (-)-Blebbistatin for Mechanobiology Workflows

  2026-09-08

  Use (-)-Blebbistatin to separate cell-generated traction from externally applied shear in mechanotransduction, cytoskeletal, and contractility assays. Its reversible non-muscle myosin II inhibition adds a practical perturbation layer to studies of GABAB receptor activation, astrocyte remodeling, migration, and actomyosin-dependent mechanics.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-08

  A 2025 GeroScience study engineered drug-sensitized Saccharomyces cerevisiae strains to expose TOR-dependent growth inhibition at substantially lower concentrations than wild-type yeast. The platform improved detection of established TOR inhibitors, identified aminophylline as a TOR1-dependent growth inhibitor, and provided no evidence that the tested cardiovascular comparator inhibited TOR in this model.

• NVP-BGJ398 phosphate: FGFR Assay Workflows

  2026-09-07

  NVP-BGJ398 phosphate enables genotype-aware inhibition of FGFR1–3 signaling across cancer and skeletal disease models. This guide connects pathway assays, chondrocyte phenotyping, and troubleshooting strategies to help researchers distinguish target engagement from nonspecific toxicity.

• Epacadostat: A Functional IDO1 Assay Strategy

  2026-09-07

  Epacadostat (INCB024360) links nanomolar IDO1 inhibition to functional immune-readout design. This guide explains how to integrate biochemical, cellular, and whole-blood assays while avoiding overinterpretation of cytokine data.

• Prion-Based Mutagenesis and Rapid Adaptation

  2026-09-05

  A 2026 Cell study shows that prion-like protein self-assembly can reversibly and heritably tune DNA repair and recombination, changing mutation patterns and adaptive trajectories in yeast. Its cross-species experiments connect protein-based epigenetic memory with accelerated drug resistance and identify prion-maintenance machinery as a potential control point.

• Cediranib (AZD2171) for Better Cancer Assays

  2026-09-04

  Cediranib (AZD2171) helps separate VEGFR target engagement from downstream growth and death phenotypes in angiogenesis and cancer research. This workflow combines time-resolved signaling, endothelial assays, and orthogonal viability measurements to produce more interpretable responses than a single endpoint.

• Optimizing hiPSC Platelet Differentiation: Key Findings

  2026-09-04

  A 2026 study developed an optimized differentiation scheme that increases megakaryocyte and platelet output from human induced pluripotent stem cells while shortening production time and lowering costs. Its combination of embryoid body optimization, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds offers a practical framework for scalable platelet biomanufacturing.

• Ranolazine: Metabolic Leverage in Translational Research

  2026-09-03

  Ranolazine offers translational researchers a way to connect late sodium current biology with myocardial energetics, relaxation, and hepatic metabolic phenotypes. This article develops a disciplined framework for using the compound in cardiac ischemia research while defining what can—and cannot—be inferred from emerging HBV–TBK1–autophagy findings.

• Pterostilbene Mitigates Dermal Senescence via Mitophagy

  2026-09-03

  Zhou et al. show that pterostilbene reduces senescence in human dermal fibroblasts by improving mitochondrial quality and promoting mitophagy. The study links mitochondrial morphology, membrane potential, reactive oxygen species, respiration, and collagen expression across cellular and UVB-exposed mouse models, while also defining practical considerations for reproducible senescence assays.

• Cediranib (AZD2171) In Vitro Assay Guide

  2026-09-02

  Cediranib (AZD2171) enables researchers to connect VEGFR pathway suppression with angiogenesis, proliferation, and cell-death measurements. This practical guide shows how to build more informative dose-response workflows and troubleshoot discordant pathway and viability results.

• Triiodothyronine (T3): From Signaling to Translation

  2026-09-02

  A translational framework for using Triiodothyronine to interrogate receptor-driven metabolism while learning from spatially concentrated base editing in oligodendrocytes. The article connects assay design, reagent rigor, and disease-model strategy without overstating cross-domain evidence.

8427 records 1/562 page Next 12345 下5页 Last page